DNA Sequencing Market By End-Use (Academic Research, Clinical Research, Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, Other Users), By Workflow (Pre-sequencing, Sequencing, Data Analysis), By Product (Consumables, Instruments, Services), By Geography, Size, Share and Global Report, Forecast 2021-2030

Published On: Apr-2022 Base Year: 2021 No Of Pages: 135 Historical Data: 2015 - 2019 Formats: PDF Report ID: 46599212

Industry Report and Statistics

The global DNA sequencing market will witness a robust CAGR of 17.12%, valued at $10.5 billion in 2021, expected to appreciate and reach $44 billion by 2030, confirms Strategic Market Research. In 2019, North America had the highest DNA sequencing market size, with 44.3% of its total revenue share. DNA sequencing is a laboratory method to determine the sequences of bases {adenine (A), cytosine (C), guanine (G) and thymine (T)} in a DNA molecule. A sample containing the DNA to be sequenced is prepared. The target sequence is then amplified using polymerase chain reaction (PCR). The amplicons obtained are then purified thoroughly, followed by preparations for the sequencing of the DNA. The DNA is then sequenced to obtain the required data, which is then analyzed thoroughly. It has been declared by the National Human Genome Research Institute (NHGRI) that all human beings are 99.9% identical in their genetic makeup. The remaining 0.1% is studied using DNA sequencing to determine the causes of the diseases. This technique has extensive applications in molecular biology, evolutionary biology, metagenomics, virology, medicine, and forensic investigations.

Market Drivers - Technological Advancements in DNA sequencing, Increasing Application in Clinical Diagnosis and Drug Discovery

Technological improvements in DNA sequencing have helped immensely to drive the market growth. According to the NHGRI, since the completion of the Human Genome Project, technological advancements and improvements have gained speed and lowered costs to a point where some labs can sequence over 100 trillion bases per year. DNA sequencing equipment like the Biomek 4000, Hudson Robotics SOLO, Formulatrix Mantis, Hamilton Microlab NIMBUS, Hamilton Genomic STARlet, Eppendorf epMotion 5075t, Beckman Coulter Biomek i5, Tecan NGS, PerkinElmer Sciclone G3 NGS and NGSx Workstation, Hamilton NGS STAR, Beckman Coulter Biomek i7, and the Agilent Bravo NGS have ameliorated the process involved in DNA sequencing.

DNA sequencing technology held more significant potential in clinical research. According to the NIH, about 7000 rare diseases affect 25 to 30 million Americans. Rare diseases are mostly caused by genetic disorders. Thus, genomic sequencing-based diagnosis can be used in rare-disease management, positively impacting the market growth.

Market Restraints - High Costs, Lack of Professional Expertise and Data Privacy

The machines used in different stages of DNA sequencing are found to be expensive. The National Human Genome Research Institute estimated that the total cost of the procedure amounts to around USD 300 million. This could hinder DNA sequencing, causing a roadblock in its market growth.

Professional expertise in DNA sequencing is not available everywhere. Thus, niche methods and products in DNA sequencing take a longer time to be discovered, thus impeding the market growth.

Genetic data privacy is a significant concern for patients, hindering the market growth. According to a study by the NCBI, only 10% of biopharmaceutical companies completely anonymized their data. The non-anonymization of data by such companies could lead to data theft and exploitation by different companies, which could impede the market growth.

Market Opportunities - Adoption of Newer Procedures

The increased usage of newer procedures in DNA sequencing can eventually boost the market growth. Methods like high-throughput sequencing, ion-torrent sequencing, pyrosequencing, single-molecule real-time sequencing, sequencing by synthesis, sequencing by ligation, combinatorial probe anchor synthesis, GenapSys sequencing, Sanger sequencing and Nanopore sequencing that employ electrical tunnelling, hybridisation, mass spectrometry, in vitro virus mRNA display, microscopy and microfluidics that can be used in DNA sequencing, DNA synthesis, RNA sequencing, gene sequencing, and sample preparation for DNA and RNA polymerase are expected to provide ample growth opportunities for the market in future.

Further, Newer cDNA sequencing methods are also being discovered. It is also because cDNA sequencing methods are regarded as one of the major opportunity providers for market growth in the future. A cDNA is a DNA strand generated in vitro from cellular mRNA.

Market Analysis Of Different Segments Covered in the Report

Based on Product

Consumables
Instruments
Services

Based on Technology

Sanger Sequencing
Next-Generation Sequencing (NGS)
- Whole Genome Sequencing (WGS)
- Whole Exome Sequencing (WES)
- Targeted Sequencing and Resequencing
Third Generation DNA Sequencing
- Single-Molecule Real-Time Sequencing (SMRT)
- Nanopore Sequencing

Based on Workflow

Pre-sequencing
Sequencing
Data Analysis

Based on Application

Oncology
Reproductive health
Clinical Investigation
Agri genomics and Forensics
HLA Typing/Immune System Monitoring
Metagenomics, Epidemiology and Drug Development
Consumer Genomics
Others

Based on End-Use

Academic Research
Clinical Research
Hospitals and Clinics
Pharmaceutical and Biotechnology Companies
Other Users

DNA sequencing Market Based on Application

Regional Coverage Analysis

North America

United States of America
Canada
Mexico
Rest of North America

Europe

Germany
United Kingdom
France
Italy
Spain
Rest of Europe

Asia-Pacific

China
Japan
India
Rest of APAC

LAMEA

Brazil
Argentina
UAE
Rest of LAMEA

Segments Analysis & Insights

Based on product, Consumables held the largest DNA sequencing market share of 43% in 2019. The wide availability of reagents and kits to cater to library construction, such as DNA fragmentation, enrichment, adapter ligation, amplification, and quality control, contributed to the maximum share in this segment.

Based on technology, the Next-Generation Sequencing (NGS) segment held the largest market share of 58.6% in 2019. Next-Generation Sequencing is the method of high-throughput DNA sequencing to determine the complete genome sequence of an organism. The advances in technology and the reducing cost of sequencing have made genome sequencing faster, more affordable, and more accurate. According to a study published in the NCBI, NGS usually took less than a day to complete. In contrast, Sanger sequencing took over a decade. According to National Human Genome Research Institute, due to continuous innovations, the cost of NGS per genome is USD 562, and the cost of NGS per megabase is USD 0.006 in August 2021. According to the American Journal of Clinical Pathology, 98.7% of DNA sequencing cases using NGS were successful. The whole-genome sequencing market size is expected to grow significantly from 2020 to 2030. Whole-genome sequencing was instrumental in determining the virus behind COVID-19.

Based on workflow, the Sequencing segment held the maximum revenue share of 52.9% in 2019. Sequencing enables the sequence profiling of the genome and DNA-protein interactions.

Based on application, the Oncology segment comprehensively dominated the market for DNA sequencing with a share of 24.4% in 2019. This technology has the maximum potential for developing cancer diagnostics and therapeutics. According to the National Centre for Health Statistics, around 2 million new cancer cases and 600,000 cancer-related deaths are expected by 2022. The increasing number of cancer cases proliferates the demand for new cancer diagnostics and therapeutics, which drives the segment’s growth.

The metagenomics, epidemiology and DNA sequencing in the drug discovery market segment is expected to grow at a CAGR of around 17.5 per cent from 2020 to 2030. According to the American Society for Clinical Pharmaceuticals and Therapeutics, the success rate of a drug, from inception to market approval, is only 10-20%. DNA sequencing can be used to improve the success rate, which would boost this segment’s market growth further.

Based on end-use, the academic research segment dominated the market with a revenue share of 55.4% in 2019 due to the increased acceptance and usage of Sanger technology and NGS in academic and institutional research projects.

Based on Region, North America has dominated significantly with a market revenue share of 44.3% in 2019. High investment in R&D, continuous technological developments by key players, and availability of technologically advanced healthcare infrastructure have resulted in North America’s more significant revenue share in the market. Asia-Pacific is expected to have substantial growth in this market. The Chinese DNA sequencing market is expected to grow at a CAGR of 19% from 2017 to 2022.

DNA Sequencing Market Report Coverage

Report Attribute	Details
Forecast Period	2021 - 2030
Market size value in 2021	USD 10.5 billion
Revenue forecast in 2030	USD 44 billion
Growth rate	CAGR of 17.12%
The base year for estimation	2021
Historical data	2017 – 2020
Unit	USD Billion, CAGR (2021 - 2030)
Segmentation	By product, By technology, By workflow, by application, By end-use and By region.
By Product	Consumables, Instruments, Services
By Technology	Sanger Sequencing, Next-Generation Sequencing (NGS), Third Generation DNA Sequencing
By Workflow	Pre-sequencing, Sequencing, Data Analysis
By Application	Oncology, Reproductive health, Clinical Investigation, Agri genomics and Forensics, HLA Typing/Immune System Monitoring, Metagenomics, Epidemiology and Drug Development, Consumer Genomics, Others
By End-Use	Academic Research, Clinical Research, Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, Other Users
By Region	Asia Pacific, North America, Europe, and LAMEA
Country Scope	US, Mexico, Canada, Germany, UK, France, China, Japan, India etc.
Company Usability Profiles	Merck KGaA, Thermo Fischer Scientific, Inc., Agilent Technologies, Inc., Illumina, Inc., F. Hoffman-La Roche Ltd., Siemens Healthineers AG, Pacific Biosciences, Eppendorf, OpenTrons, Gilson, Neotec, TTP Labtech Ltd., Beckman Coulter, Element Biosciences, Inc.
Pricing and purchase options	Customized buying options are available to meet your exact research needs.

Global DNA Sequencing Market Competitive Landscape Analysis

The market is very competitive and has a few significant players. These companies make substantial efforts to address consumer demand. They make substantial investments in production, distribution, and total quality management for their portfolio expansion. The key players in this market are:

Merck KGaA
Thermo Fischer Scientific, Inc.
Agilent Technologies, Inc.
Illumina, Inc.
F. Hoffman-La Roche Ltd.
Siemens Healthineers AG
Pacific Biosciences
Eppendorf
OpenTrons
Gilson
Neotec
TTP Labtech Ltd.
Beckman Coulter
Element Biosciences, Inc.

DNA sequencing Market Based on Region

Recent Developments

In March 2022, Element Biosciences, Inc. announced the commercial launch of its Element AVIT system. Element believes that through this product launch, the company is delivering on its vision to expand access to high-quality, low-cost, and easy to use genomics tools.

In March 2022, Illumina announced its partnership with Trivitron to develop next-generation sequencing (NGS) based in-vitro diagnostic (IVD) tests In India. Illumina believes that the company can make genomic technology and precision medicine available for all through this partnership.

In January 2021, SPT Labtech announced its collaboration with Thermo Fisher Scientific to jointly market solutions that could enable variant detection at a fraction of the cost. SPT Labtech and Thermo Fisher believe that by automating and miniaturising NGS processes, scientists can expand their research’s scope and ultimately generate insights into human health.

In May 2020, F. Hoffman-La Roche Ltd. announced the acquisition of Stratos Genomics to advance the development of Roche’s nanopore sequencer. Roche believes that the acquisition can help address clinical research demands, which could help resolve patient needs.

In January 2020, Agilent Technologies, Inc. announced the launch of its Agilent SureSelect XT HS2 DNA kit to address key challenges laboratories might encounter while preparing DNA sequencing libraries. Agilent Technologies believes that the kit will help laboratory scientists accelerate their capture-based enrichment library preparation without sacrificing quality.

Various Leading DNA Sequencing Devices that Key Market Leaders Develop

Name of the Product	Function	Company
OpenTrons OT-2	Pipetting for genomics, proteomics, cell-based assays and drug discovery	OpenTrons
Gilson Pipetmax	Pipetting for biological assays	Gilson
Neotec EzMate	Pipetting for PCR/ qPCR sample preparation	Neotec
TTP Labtech Mosquito HV Genomics	Pipetting for miniaturised molecular biology	TTP Labtech Ltd.
Beckman Coulter Labcyte Echo 525	Biochemical and Genomics Reagent Transfer	Beckman Coulter

Frequently Asked Question About This Report

b: The major factors that contribute to the growth of the market are technological advancements in DNA sequencing and increasing applications in clinical diagnosis and drug discovery.

b: The Next-Generation Sequencing segment held the highest share in the market based on technology, with a revenue share of 58.6% in 2019.

b: The oncology segment held the maximum revenue share in the market, with a share of 24.4% in 2019.

b: The North American region held the most significant revenue share in the market, with a revenue contribution of 44.3% in 2019.

b: The global DNA sequencing market is expected to grow at a compound annual growth rate (CAGR) of 17.12 % from 2021 to 2030 to reach USD 44 Billion by 2030.

b: The global DNA sequencing market size was $ 10.5 Bn in 2021 and is predicted to reach $ 44 Bn by 2030, with a CAGR of 17.12 %.

Sources

https://www.genome.gov/17516714/2006-release-about-whole-genome-association-studies

https://rarediseases.org/wp-content/uploads/2019/01/RDD-FAQ-2019.pdf

https://www.genome.gov/about-genomics/fact-sheets/Sequencing-Human-Genome-cost

https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12980

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161442/

https://sapac.illumina.com/science/technology/next-generation-sequencing/beginners/ngs-cost.html